ADMA Biologics (NASDAQ: ADMA) reported Q4 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $49.98 million versus the consensus estimate of $45.93 million.

GUIDANCE:

ADMA Biologics sees FY2023 revenue of $210 million, versus the consensus of $211 million.

ADMA Biologics sees FY2023 revenue of $250 million, versus the consensus of $258.7 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.